If you own or are considering buying pharma laggards Pfizer (NYSE: PFE), Bristol Myers Squibb (NYSE: BMY), and Merck (NYSE: ...

Obesity is a growing problem that now has effective treatments. Pfizer has been eager to develop a strong position in this area. This acquisition gives Pfizer a viable obesity drug candidate. Pfizer's ...

As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Pfizer (NYSE:PFE) and its peers.

Pfizer will buy Metsera for at least $47.50 per share. Pfizer could end up paying closer to $70 per share. Pfizer wants to sell GLP-1 weight loss drugs, and Metsera has four such candidates.

Shares of several major vaccine makers lost ground Monday following a report U.S. vaccine approval rules could become ...

Pfizer's CEO certainly thinks so. In a TV interview, Bourla said: "Pfizer, when it plays, plays big. And we will -- as we did in COVID, as we did with Lipitor, as we did with ... Viagra, as we did ...

Remember Pfizer (NYSE: PFE), the giant pharmaceutical company that developed a COVID-19 vaccine within weeks of the pandemic hitting U.S. shores and got it approved within a year? It was the fastest ...